A randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) plus placebo to mobilize and collect greater than or equal to 6x10e6 CD34+ cells/kg in multiple myeloma patients for autologous transplantation
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Plerixafor (Primary) ; Filgrastim
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- Sponsors AnorMED
- 13 Apr 2022 New trial record